TargetMol

Zeniplatin

Product Code:
 
TAR-T35300
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T35300-1mg1mg£208.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35300-5mg5mg£412.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35300-10mg10mg£575.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35300-25mg25mg£860.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35300-50mg50mg£1,155.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35300-100mg100mg£1,532.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Zeniplatin is a biochemical.
CAS:
111490-36-9
Formula:
C11H18N2O6Pt
Molecular Weight:
469.357
Purity:
0.98
SMILES:
OCC1(CO)CN[Pt++]2(NC1)[O-]C(=O)C1(CCC1)C(=O)[O-]2

References

DeMarco LC, Budman DR, Lathia C, Amorusi P, Birkhofer M, Lichtman S, Weiselberg L, Vinciguerra V, Lovecchio J, Gal D, et al. Pharmacokinetic evaluation of zeniplatin in humans. Cancer Chemother Pharmacol. 1995;36(1):35-40. PubMed PMID: 7720173. Sorensen JB. Treatment of non-small cell lung cancer: new cytostatic agents. Lung Cancer. 1993 Dec;10(3-4):173-87. Review. PubMed PMID: 8075965. Olver I, Green M, Peters W, Zimet A, Toner G, Bishop J, Ketelbey W, Rastogi R, Birkhofer M. A phase II trial of zeniplatin in metastatic melanoma. Am J Clin Oncol. 1995 Feb;18(1):56-8. PubMed PMID: 7847260. Aamdal S, Bruntsch U, Kerger J, Verweij J, ten Bokkel Huinink W, Wanders J, Rastogi R, Franklin HR, Kaye SB. Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity. Cancer Chemother Pharmacol. 1997;40(5):439-43. PubMed PMID: 9272122.